Author: healthylife7

LONDON, July 10, 2026 /PRNewswire/ — Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the “Ordinary Shares”) originally issued in October 2023 (as amended in December…

Read More